Headlands Technologies LLC Makes New $90,000 Investment in Kodiak Sciences Inc. (NASDAQ:KOD)

Headlands Technologies LLC bought a new stake in Kodiak Sciences Inc. (NASDAQ:KOD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 9,070 shares of the company’s stock, valued at approximately $90,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC raised its position in shares of Kodiak Sciences by 26.4% during the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares during the last quarter. State Street Corp raised its holdings in shares of Kodiak Sciences by 1.8% in the third quarter. State Street Corp now owns 816,634 shares of the company’s stock worth $2,131,000 after acquiring an additional 14,711 shares during the last quarter. Barclays PLC lifted its position in shares of Kodiak Sciences by 65.5% in the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after acquiring an additional 31,527 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Kodiak Sciences by 1.7% during the third quarter. Geode Capital Management LLC now owns 768,740 shares of the company’s stock valued at $2,007,000 after acquiring an additional 12,783 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after purchasing an additional 30,735 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on KOD. HC Wainwright reaffirmed a “neutral” rating and set a $3.00 price target on shares of Kodiak Sciences in a research note on Monday, March 31st. Jefferies Financial Group upgraded shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Monday, December 9th.

Kodiak Sciences Trading Down 2.1 %

Shares of NASDAQ:KOD opened at $2.35 on Monday. The firm has a market cap of $123.96 million, a price-to-earnings ratio of -0.64 and a beta of 2.40. The stock’s 50-day moving average price is $4.32 and its two-hundred day moving average price is $5.44. Kodiak Sciences Inc. has a 12-month low of $2.10 and a 12-month high of $11.60.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.06. As a group, research analysts forecast that Kodiak Sciences Inc. will post -3.45 earnings per share for the current fiscal year.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.